Pinealon: Glu-Asp-Arg and the Short-Peptide Bioregulator Concept

Pinealon is a synthetic tripeptide with the sequence Glu-Asp-Arg, often abbreviated EDR. It comes from the same St. Petersburg research school, led by Vladimir Khavinson, that produced epitalon and a series of other very short peptides described as bioregulators. The pinealon literature is small and concentrated, but it is a useful entry point into the short-peptide bioregulator concept as a whole: the idea that peptides of two to four residues, derived from the composition of tissue extracts, can influence gene expression in specific cell types.

This article sets out what is known about pinealon at the level of chemistry, the kinds of cell and animal models in which it has been studied, the DNA-interaction hypotheses proposed to explain the reported findings, and the limits of that evidence. Incredible Peptides does not supply pinealon, and this profile is a literature review only; the related defined short peptides it does supply sit in its bioregulator peptides range.

Structure and physicochemical properties

Pinealon is about as small as a bioactive peptide can be. Its three residues give it the molecular formula C₁₅H₂₆N₆O₈ and an average molecular weight of roughly 418.4 g/mol, with a monoisotopic mass near 418.181 Da. The N-terminus is a free amine and the C-terminus a free acid. At neutral pH the molecule carries a protonated N-terminus and a protonated arginine guanidinium group on one side, and carboxylates from glutamate, aspartate and the C-terminus on the other, giving a net charge of about minus one.

Two chemical features deserve attention. An N-terminal glutamic acid can cyclise to pyroglutamate, losing water (18 Da) and the free N-terminal amine; the reaction is slower than the equivalent cyclisation of glutamine but is well documented under heating and mildly acidic conditions. The internal aspartate can also isomerise through a succinimide intermediate to isoaspartate, although this is much slower at Asp-Arg than at the notorious Asp-Gly motif. Both modifications should be considered when interpreting chromatograms of aged material. Like other very polar short peptides, pinealon retains poorly on standard C18 reversed-phase columns, and it has no aromatic residue, so UV detection depends on the peptide bond region near 214 nm.

The short-peptide bioregulator concept

The bioregulator programme began with crude polypeptide extracts from animal organs, such as epithalamin from bovine pineal gland and thymalin from calf thymus. The group then analysed the amino acid composition of these preparations and synthesised di-, tri- and tetrapeptides intended to reproduce their activity in a defined, synthetic form. The resulting compounds include the tetrapeptide epitalon (Ala-Glu-Asp-Gly), the dipeptides Lys-Glu and Glu-Trp, and the tripeptide Glu-Asp-Arg. Pinealon was designed within this same programme.

The central claim of the concept is tissue specificity: that each short peptide acts preferentially on cells from the organ whose extract it was modelled on. That is a strong and testable claim. It predicts that sequence matters, that scrambled peptides of identical composition should behave differently, and that effects should appear selectively in the relevant cell types. The broader family is reviewed in the overview of bioregulator peptides.

Research in cell and animal models

Published pinealon work falls into two broad groups. The first is cell culture, where the peptide has been examined in neuronal and other cell types exposed to oxidative stressors, with readouts such as reactive oxygen species levels, cell viability, markers of cell-cycle activity and the expression of selected genes. The second is a smaller set of rodent studies, mostly from the same group and collaborators, in which the peptide was given to animals in models of oxidative or metabolic stress and tissue markers were measured afterwards. Both categories are preclinical, and the rodent findings should not be extrapolated beyond the specific models used.

Several features of this literature limit its interpretation. Most studies come from one network of laboratories. Sample sizes are often small, assay details are not always fully reported, and material characterisation, meaning HPLC purity, mass confirmation and counterion content of the peptide used, is rarely described in depth. Few studies include a scrambled-sequence control such as Asp-Glu-Arg or Arg-Asp-Glu, which is the most direct way to show that an effect depends on the EDR sequence rather than on any small charged peptide. The general principles are covered in the article on experimental controls in peptide research.

DNA-interaction hypotheses

To explain how such small molecules could act on gene expression, the Khavinson group proposed that short peptides enter the cell and the nucleus and bind directly to DNA, for example to particular sequences in promoter regions, or to histone proteins, thereby altering chromatin accessibility and transcription. The supporting evidence includes molecular modelling and docking studies, spectroscopic measurements of peptide-DNA binding, and gene-expression changes in exposed cultures. These should be read as hypotheses rather than as an established mechanism.

There are good biophysical reasons for caution. Sequence-specific DNA recognition by proteins normally relies on extended interfaces, typically an alpha-helix or beta-strand in the major groove making many hydrogen bonds and van der Waals contacts with bases, plus backbone contacts that position the recognition element. A tripeptide offers only a handful of potential contacts. Its arginine side chain will interact electrostatically with the phosphate backbone, but that kind of binding is largely nonspecific and is seen with many cationic peptides. Demonstrating specificity would require orthogonal methods, such as isothermal titration calorimetry, surface plasmon resonance or DNase footprinting, with matched scrambled peptides and control DNA sequences. The related tetrapeptide epitalon is the subject of comparable proposals and faces the same evidentiary question.

Limits of the evidence and how to read it

Taken together, the pinealon literature amounts to an interesting set of preclinical observations and a mechanistic proposal that has not been independently confirmed. Independent replication, rigorous characterisation of the material used, concentration-response data and sequence controls are the main gaps. None of these points disproves the reported findings; they simply define what would be needed to move them from hypothesis to accepted pharmacology.

For laboratories interested in the chemistry of short bioregulator-type peptides, the defined sequences that are available, such as epitalon and the other entries in the bioregulators category, offer a practical model system for exploring isomerisation, pyroglutamate formation, HILIC and ion-pair chromatography, and the analytical challenges of very polar peptides. All such materials are for laboratory research use only; they are not for human or veterinary use.

A small peptide with a large hypothesis

Pinealon illustrates the bioregulator idea in its most compressed form: three residues, a proposed gene-regulatory role and a literature concentrated in one school. Its chemistry is straightforward to define and verify. Its biology rests on preclinical reports and on DNA-binding hypotheses that face genuine biophysical objections. Careful researchers will regard it as an open question and design experiments, with scrambled controls and orthogonal binding assays, capable of answering it.

References

1. Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Journal of Biological Chemistry. 1987.
2. Chelius D, Jing K, Lueras A, et al. Formation of pyroglutamic acid from N-terminal glutamic acid in immunoglobulin gamma antibodies. Analytical Chemistry. 2006.
3. Luscombe NM, Laskowski RA, Thornton JM. Amino acid-base interactions: a three-dimensional analysis of protein-DNA interactions at an atomic level. Nucleic Acids Research. 2001.